Quetiapine + Haloperidol + Lorazepam + Cogentin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Agitation
Conditions
Agitation
Trial Timeline
May 1, 2006 → May 1, 2009
NCT ID
NCT00457366About Quetiapine + Haloperidol + Lorazepam + Cogentin
Quetiapine + Haloperidol + Lorazepam + Cogentin is a approved stage product being developed by AstraZeneca for Agitation. The current trial status is completed. This product is registered under clinical trial identifier NCT00457366. Target conditions include Agitation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00457366 | Approved | Completed |
Competing Products
20 competing products in Agitation